A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

被引:45
|
作者
Pantuck, A. J. [1 ]
Pettaway, C. A. [2 ]
Dreicer, R. [3 ]
Corman, J. [4 ]
Katz, A. [5 ]
Ho, A. [5 ]
Aronson, W. [1 ,6 ]
Clark, W. [7 ]
Simmons, G. [8 ]
Heber, D. [1 ,9 ]
机构
[1] Univ Calif Los Angeles, Dept Urol, Inst Urol Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Winthrop Univ Hosp, Garden City, NY USA
[6] VA Med Ctr Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[7] Alaska Clin Res Ctr, Anchorage, AK USA
[8] Five Valleys Urol, Missoula, MT USA
[9] Univ Calif Los Angeles, Dept Med & Clin Nutr, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
MANGANESE SUPEROXIDE-DISMUTASE; FACTOR-KAPPA-B; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; PHASE-II; GROWTH; CARCINOGENESIS; RADIATION; JUICE; RISK;
D O I
10.1038/pcan.2015.32
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer. METHODS: Double-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT. RESULTS: One-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2: 1 (extract N = 102; placebo N = 64; juice N = 17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P < 0.001) compared with an increase from 12.9 months at baseline to 14.5 months in the extract group (P = 0.13) and an increase from 12.7 at baseline to 20.3 in the juice group (P = 0.004). However, none of these changes were statistically significant between the three groups (P > 0.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P = 0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P = 0.03). CONCLUSIONS: Compared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 50 条
  • [21] Immunomodulatory Effects of ResistAid™: A Randomized, Double-Blind, Placebo-Controlled, Multidose Study
    Udani, Jay K.
    JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2013, 32 (05) : 331 - 338
  • [22] Effects of Febuxostat in Early Gout A Randomized, Double-Blind, Placebo-Controlled Study
    Dalbeth, Nicola
    Saag, Kenneth G.
    Palmer, William E.
    Choi, Hyon K.
    Hunt, Barbara
    MacDonald, Patricia A.
    Thienel, Ulrich
    Gunawardhana, Lhanoo
    ARTHRITIS & RHEUMATOLOGY, 2017, 69 (12) : 2386 - 2395
  • [23] Effects of levetiracetam on tardive dyskinesia: A randomized, double-blind, placebo-controlled study
    Woods, Scott W.
    Saksa, John R.
    Baker, C. Bruce
    Cohen, Shuki J.
    Tek, Cenk
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (04) : 546 - 554
  • [24] PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND STUDY OF INCOBOTULINUMTOXINA FOR SIALORRHEA
    Jost, W.
    Friedman, A.
    Michel, O.
    Oehlwein, C.
    Slawek, J.
    Bogucki, A.
    Ochudlo, S.
    Banach, M.
    Pagan, F.
    Flatau-Baque, B.
    Csikos, J.
    Cairney, C. J.
    Blitzer, A.
    PARKINSONISM & RELATED DISORDERS, 2023, 113 : 40 - 40
  • [25] Alendronate in primary hyperparathyroidism: A double-blind, randomized, placebo-controlled trial
    Khan, AA
    Bilezikian, JP
    Kung, AWC
    Ahmed, MM
    Dubois, SJ
    Ho, AYY
    Schussheim, D
    Rubin, MR
    Shaikh, AM
    Silverberg, SJ
    Standish, TI
    Syed, Z
    Syed, ZA
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (07): : 3319 - 3325
  • [26] CETACAINE EFFICACY - A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY
    LACHTER, J
    JACOBS, R
    LAVY, A
    SUISSA, A
    WEISLER, A
    EIDELMAN, S
    GASTROENTEROLOGY, 1988, 94 (05) : A245 - A245
  • [27] Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa in Men With Castration-Resistant Prostate Cancer and Anemia
    Winquist, Eric
    Julian, Jim A.
    Moore, Malcolm J.
    Nabid, Abdenour
    Sathya, Jinka
    Wood, Lori
    Venner, Peter
    Levine, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (04) : 644 - 646
  • [28] The Effects of Monosodium Glutamate on PSMA Radiotracer Uptake in Men with Recurrent Prostate Cancer: A Prospective, Randomized, Double-Blind, Placebo-Controlled Intraindividual Imaging Study
    Harsini, Sara
    Saprunoff, Heather
    Alden, Tina
    Mohammadi, Behnoud
    Wilson, Don
    Benard, Francois
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (01) : 81 - 87
  • [29] A phase 3, randomized, double-blind, placebo-controlled study of tasquinimod (TASQ) in men with metastatic castrate resistant prostate cancer (mCRPC)
    Carducci, M.
    Armstrong, A.
    Pili, R.
    Ng, S.
    Huddart, R.
    Agarwal, N.
    Khvorostenko, D.
    Lyulko, O.
    Brize, A.
    Vogelzang, N. J.
    Delva, R.
    Harza, M.
    Thanos, A.
    James, N.
    Werbrouck, P.
    Boegemann, M.
    Hutson, T.
    Milecki, P.
    Nederman, T.
    Sternberg, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S713 - S714
  • [30] A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia
    LeBars, PL
    Katz, MM
    Berman, N
    Itil, TM
    Freedman, AM
    Schatzberg, AF
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (16): : 1327 - 1332